TABLE IV.
Summary of base-case probabilistic results
| Treatment option | Mean cycles in mds on treatment (n) | Total costs (2012 CA$) |
Total
|
Incremental
|
Cost per ly gained by azacitidine [CA$/ly (95% ci)] | Incremental cost per qaly gained by azacitidine [CA$/qaly (95% ci)] | |||
|---|---|---|---|---|---|---|---|---|---|
| lys | qalys | Costs incurred by azacitidine (2012 CA$) | lys gained by azacitidine | qalys gained by azacitidine | |||||
| ccrs combineda | |||||||||
| Azacitidine | na | 112,354 | 2.51 | 1.96 | |||||
| ccrs | na | 35,908 | 1.50 | 1.06 | 76,446 | 1.01 | 0.90 | 75,871 (71,416 to 80,767) | 86,182 (69,920 to 107,157) |
| Specific ccrs | |||||||||
| Preselected for bsc | |||||||||
| Azacitidine | 10.59 | 111,414 | 2.50 | 1.95 | 77,897 | 1.02 | 0.91 | 76,567 (71,675 to 81,550) | 86,973 (70,076 to 110,051) |
| bsc | 15.58 | 33,517 | 1.48 | 1.05 | |||||
| Preselected for ldc | |||||||||
| Azacitidine | 10.95 | 114,368 | 2.53 | 1.98 | 73,336 | 0.99 | 0.88 | 74,514 (67,083 to 82,932) | 84,829 (66,863 to 108,691) |
| ldc | 6.08 | 41,032 | 1.55 | 1.10 | |||||
| Preselected for sdc | |||||||||
| Azacitidine | 10.91 | 110,337 | 2.23 | 1.74 | 1,850 | 0.87 | 0.71 | 2,636 (Dominant, 25,819) | 2,152 (Dominant, 19,869) |
| sdc | 2.22 | 108,486 | 1.36 | 1.03 | |||||
a
The weights of 68% for bsc and 32% for low-dose chemotherapy from the aza-001 trial were applied to calculate the results of comparing the combined conventional care regimens to azacitidine. Standard-dose chemotherapy was excluded from the combination as the base-case results showed it was a cost-ineffective comparator relative to low-dose chemotherapy.
mds = myelodysplastic syndrome; ly = life year; qaly = quality-adjusted life year; ci = confidence interval; ccrs = conventional care regimens; bsc = best supportive care; ldc = low-dose chemotherapy; sdc = standard-dose chemotherapy.